Trials / Completed
CompletedNCT02260557
Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group, Exploratory Phase 2 Study to Assess Efficacy and Safety of Selexipag in Adult Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 74 (actual)
- Sponsor
- Actelion · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to determine the activity of selexipag on Raynaud attack frequency in subjects with Raynaud's Phenomenon (RP) secondary to Systemic Sclerosis (SSc).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Selexipag | Film-coated tablets containing 200 μg of selexipag to be administered orally twice daily |
| DRUG | Placebo | Placebo matching selexipag 200 μg tablets to be administered orally twice daily |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2015-04-01
- Completion
- 2015-06-01
- First posted
- 2014-10-09
- Last updated
- 2025-02-03
Source: ClinicalTrials.gov record NCT02260557. Inclusion in this directory is not an endorsement.